相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?
Abel Botelho Quaresma et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease
Nicholas E. Burr et al.
JOURNAL OF CROHNS & COLITIS (2019)
Postoperative Approach for Crohn's Disease: The Right Therapy to the Right Patient
Paulo Gustavo Kotze et al.
CURRENT DRUG TARGETS (2018)
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease
Geert D'Haens et al.
GASTROENTEROLOGY (2018)
Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study
Claire Auzolle et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors
Shmuel Fay et al.
INFLAMMATORY BOWEL DISEASES (2017)
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases
N. Mitrev et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Factors affecting the incidence of early endoscopic recurrence after ileocolonic resection for Crohn's disease: a multicentre observational study
I. F. de Barcelos et al.
COLORECTAL DISEASE (2017)
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection
Miguel Regueiro et al.
GASTROENTEROLOGY (2016)
Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling
Karoline Freeman et al.
HEALTH TECHNOLOGY ASSESSMENT (2016)
Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease
Clare Moore et al.
JOURNAL OF CROHNS & COLITIS (2016)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Direct Retrospective Comparison of Adalimumab and Infliximab in Preventing Early Postoperative Endoscopic Recurrence After Ileocaecal Resection for Crohn's Disease: Results from the MULTIPER Database
Paulo Gustavo Kotze et al.
JOURNAL OF CROHNS & COLITIS (2015)
Crohn's disease management after intestinal resection: a randomised trial
Peter De Cruz et al.
LANCET (2015)
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study
Alessandro Armuzzi et al.
Journal of Crohns & Colitis (2013)
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response
Lior Katz et al.
INFLAMMATORY BOWEL DISEASES (2012)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
分享论文
